论文部分内容阅读
目的 探讨IgA肾病患者血浆肾上腺髓质素 (ADM)水平及其临床意义。方法 检测 3 5例IgA肾病患者及 2 2例正常人血浆ADM水平 ,分析患者血浆ADM与尿蛋白的关系。结果 IgA肾病患者血浆ADM水平为 (2 4 2± 3 8)pg/ml显著高于正常对照组 (10 9± 0 8)pg/ml(P <0 0 1) ;蛋白尿大于 1g/ 2 4h组血浆ADM(3 2 1± 4 7)pg/ml显著高于少量或无蛋白尿组 (18 1± 2 5 )pg/ml(P <0 0 5 )。结论 ADM参与了IgA肾病患者病理生理过程 ,合并明显蛋白尿的IgA肾病患者血浆ADM升高 ,可能为代偿性的保护作用。
Objective To investigate the level of plasma adrenomedullin (ADM) in patients with IgA nephropathy and its clinical significance. Methods Plasma ADM levels were measured in 35 patients with IgA nephropathy and 22 normal controls, and the relationship between plasma ADM and urinary protein was analyzed. Results Plasma ADM levels in patients with IgA nephropathy were significantly higher than those in the normal control group (P <0.001) (P <0.01); proteinuria was greater than 1 g / 24 h Plasma ADM (3 2 1 ± 4 7) pg / ml was significantly higher (18 1 ± 2 5) pg / ml (P 0 05) in patients with or without proteinuria. Conclusions ADM is involved in the pathophysiological process of patients with IgA nephropathy. Elevated plasma ADM in patients with IgA nephropathy with significant proteinuria may be a compensatory protective effect.